Advertisement

Topics

Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?

06:25 EDT 15 Sep 2018 | Cancer Networks

The combination of pembrolizumab and a TLR9 agonist known as SD-101 showed promising activity in patients with unresectable or metastatic melanoma.

Original Article: Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?

NEXT ARTICLE

More From BioPortfolio on "Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....